Shares of ADMA Biologics Inc (NASDAQ:ADMA) were up 11% during mid-day trading on Tuesday . The company traded as high as $3.05 and last traded at $2.93. Approximately 608,981 shares changed hands during trading, an increase of 791% from the average daily volume of 68,310 shares. The stock had previously closed at $2.64.

A number of analysts recently issued reports on ADMA shares. ValuEngine lowered shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Raymond James Financial upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Tuesday, November 14th. Finally, Maxim Group restated a “buy” rating and set a $8.00 target price (down previously from $13.00) on shares of ADMA Biologics in a research report on Monday, December 11th.

The company has a market capitalization of $68.09, a PE ratio of -3.83 and a beta of 2.50. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26.

In related news, insider Adam S. Grossman purchased 485,000 shares of the firm’s stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $2.15 per share, for a total transaction of $1,042,750.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Eric I. Richman purchased 25,000 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was bought at an average price of $2.15 per share, for a total transaction of $53,750.00. Following the acquisition, the director now owns 31,300 shares in the company, valued at $67,295. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 526,500 shares of company stock worth $1,131,975. 60.44% of the stock is owned by company insiders.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 565,000 shares of the biotechnology company’s stock after acquiring an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned about 2.19% of ADMA Biologics worth $1,740,000 as of its most recent SEC filing. Institutional investors own 32.78% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ADMA Biologics (ADMA) Trading 11% Higher” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with Analyst Ratings Network's FREE daily email newsletter.